NASDAQ$TNGX

Tango Therapeutics Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$10.7M

Previous: $6.92M+55.1%
EPS (adj)

-$0.23

Previous: -$0.33+30.3%
Capital Expenditures

-$1.3M

Previous: -$6.65M+80.5%
Free Cash Flow

-$23.6M

Previous: -$35.7M+34.0%
Net Income

-$22.3M

Previous: -$29.1M+23.4%
Operating Income

-$25.6M

Previous: -$29.9M+14.4%
Gross Profit

$10.7M

Previous: $6.92M+55.1%
Cash & Equivalents

$361M

Previous: $100M+259.6%
Total Assets

$428M

Previous: $464M-7.7%
R&D Expense

$27.1M

No prior period
Stock-Based Comp

$4.86M

Previous: $3.82M+27.4%

Revenue & EPS history

Tango Therapeutics · Revenue · Quarterly

$10.7M

Q3 2023+55.1%vs Q3 2022
Beat estimate in 6 of 13 quarters(46%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.6%

Avg return

Earnings day

+6.7%

Avg return

5 days after

+25.8%

Avg return

30 days after

58%

11 / 19 earnings

Positive

+36.4%

Q4 2025

Best reaction

-45.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.6%-12.1%+31.7%
Q4 2025+36.4%+33.6%+75.1%
Q3 2025+0.2%-1.7%+23.6%
Q1 2025+17.1%+31.6%+315.8%
Q4 2024-6.5%-21.0%-36.9%
Q3 2024-45.4%-34.7%-34.7%
Q2 2024-1.8%-5.7%+20.9%
Q1 2024-0.8%-6.9%-12.1%
Q4 2023-9.7%-14.4%-17.4%
Q3 2023+3.8%-12.1%+6.6%
Q2 2023+1.2%+120.9%+113.5%
Q1 2023+6.4%+4.4%-0.3%
Q4 2022-9.4%-5.3%-21.6%
Q3 2022-5.3%+6.7%-1.3%
Q2 2022+22.4%+32.8%-8.1%
Q1 2022-7.6%+1.2%-3.8%
Q4 2021+0.3%+6.8%+1.3%
Q3 2021+0.4%+5.2%-10.7%
Q2 2021+1.1%-2.2%+49.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro